Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Nuclear Medicine

Free Subscription Articles published in Brain Retrieve available abstracts of 89 articles: HTML format

Single Articles

May 2021
1. HOSP JA, Dressing A, Blazhenets G, Bormann T, et al
   Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19.
   Brain. 2021;144:1263-1276.
   PubMed     Abstract available
   
   
   April 2021
2. 
   Corrigendum to: Monitoring the progression of Alzheimer's disease with tau-PET.
   Brain. 2021 Apr 6. pii: 6213355. doi: 10.1093.
   PubMed    
   
   
   March 2021
3. MAHLER C, Schumacher AM, Unterrainer M, Kaiser L, et al
   TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
   Brain. 2021 Mar 23. pii: 6184141. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. YAP SY, Frias B, Wren MC, Scholl M, et al
   Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease.
   Brain. 2021 Mar 20. pii: 6179104. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2021
5. GOODHEART AE, Locascio JJ, Samore WR, Collins JA, et al
   18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.
   Brain. 2021;144:266-277.
   PubMed     Abstract available
   
   
   
6. ARNALDI D, Chincarini A, Hu MT, Sonka K, et al
   Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.
   Brain. 2021;144:278-287.
   PubMed     Abstract available
   
   
   December 2020
7. AVRAM M, Brandl F, Knolle F, Cabello J, et al
   Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia.
   Brain. 2020;143:3495-3505.
   PubMed     Abstract available
   
   
   
8. PEREIRA JB, Janelidze S, Ossenkoppele R, Kvartsberg H, et al
   Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer's disease.
   Brain. 2020 Dec 5. pii: 6024803. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. SMITH R, Strandberg O, Mattsson-Carlgren N, Leuzy A, et al
   The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
   Brain. 2020;143:3805-3815.
   PubMed     Abstract available
   
   
   November 2020
10. SUR C, Kost J, Scott D, Adamczuk K, et al
    BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Brain. 2020 Nov 30. pii: 6012787. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. MOSCOSO A, Grothe MJ, Ashton NJ, Karikari TK, et al
    Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Brain. 2020 Nov 30. pii: 6012955. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. BENEDET AL, Leuzy A, Pascoal TA, Ashton NJ, et al
    Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Brain. 2020 Nov 19. pii: 5990278. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. SOLEIMANI-MEIGOONI DN, Iaccarino L, La Joie R, Baker S, et al
    18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Brain. 2020 Nov 3. pii: 5952719. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. BASHIR A, Vestergaard MB, Marner L, Larsen VA, et al
    PET imaging of meningioma with 18F-FLT: a predictor of tumour progression.
    Brain. 2020 Nov 3. pii: 5952713. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. LI Y, Wang T, Zhang T, Lin Z, et al
    Fast high-resolution metabolic imaging of acute stroke with 3D magnetic resonance spectroscopy.
    Brain. 2020 Nov 3. pii: 5952715. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2020
16. JACK CR, Wiste HJ, Weigand SD, Therneau TM, et al
    Predicting future rates of tau accumulation on PET.
    Brain. 2020 Oct 23. pii: 5930009. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. SUCKSDORFF M, Matilainen M, Tuisku J, Polvinen E, et al
    Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Brain. 2020 Oct 2. pii: 5917253. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2020
18. FORSBERG MOREN A, Varrone A
    Timing is everything: tau imaging across stages of Alzheimer's disease.
    Brain. 2020;143:2634-2636.
    PubMed    
    
    
    August 2020
19. HORSAGER J, Andersen KB, Knudsen K, Skjaerbaek C, et al
    Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study.
    Brain. 2020 Aug 24. pii: 5896254. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2020
20. PASCOAL TA, Therriault J, Benedet AL, Savard M, et al
    18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Brain. 2020 Jul 16. pii: 5872095. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2020
21. SINTINI I, Graff-Radford J, Senjem ML, Schwarz CG, et al
    Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Brain. 2020 Jun 23. pii: 5861030. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. DUCHARME S, Dols A, Laforce R, Devenney E, et al
    Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders.
    Brain. 2020;143:1632-1650.
    PubMed     Abstract available
    
    
    May 2020
23. MALPETTI M, Kievit RA, Passamonti L, Jones PS, et al
    Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Brain. 2020 May 7. pii: 5831943. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2020
24. SPOTORNO N, Acosta-Cabronero J, Stomrud E, Lampinen B, et al
    Relationship between cortical iron and tau aggregation in Alzheimer's disease.
    Brain. 2020 Apr 24. pii: 5824902. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. ADAMS RA, Bush D, Zheng F, Meyer SS, et al
    Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia.
    Brain. 2020;143:1261-1277.
    PubMed     Abstract available
    
    
    
26. SCHANKIN CJ, Maniyar FH, Chou DE, Eller M, et al
    Structural and functional footprint of visual snow syndrome.
    Brain. 2020;143:1106-1113.
    PubMed     Abstract available
    
    
    March 2020
27. BEVAN-JONES WR, Cope TE, Jones PS, Kaalund SS, et al
    Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum.
    Brain. 2020 Mar 17. pii: 5803192. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. JHA A, Teotonio R, Smith AL, Bomanji J, et al
    Metabolic lesion-deficit mapping of human cognition.
    Brain. 2020;143:877-890.
    PubMed     Abstract available
    
    
    
29. RUPPERT MC, Greuel A, Tahmasian M, Schwartz F, et al
    Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Brain. 2020;143:944-959.
    PubMed     Abstract available
    
    
    February 2020
30. WIESMANN M, de Leeuw FE
    Vascular reserve in brain resilience: pipes or perfusion?
    Brain. 2020;143:390-392.
    PubMed    
    
    
    January 2020
31. BETTHAUSER TJ, Koscik RL, Jonaitis EM, Allison SL, et al
    Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Brain. 2020;143:320-335.
    PubMed     Abstract available
    
    
    
32. WEISS D, Schoellmann A, Fox MD, Bohnen NI, et al
    Freezing of gait: understanding the complexity of an enigmatic phenomenon.
    Brain. 2020;143:14-30.
    PubMed     Abstract available
    
    
    
33. MATAR E, Shine JM, Halliday GM, Lewis SJG, et al
    Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework.
    Brain. 2020;143:31-46.
    PubMed     Abstract available
    
    
    December 2019
34. BLENNOW K, Chen C, Cicognola C, Wildsmith KR, et al
    Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.
    Brain. 2019 Dec 13. pii: 5675540. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2019
35. ZHANG M, Dilliott AA, Khallaf R, Robinson JF, et al
    Genetic and epigenetic study of an Alzheimer's disease family with monozygotic triplets.
    Brain. 2019 Oct 3. pii: 5580538. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. NUTMA E, Stephenson JA, Gorter RP, de Bruin J, et al
    A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Brain. 2019 Oct 3. pii: 5580333. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. GORDON BA, Tijms BM
    Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals.
    Brain. 2019;142:2903-2904.
    PubMed    
    
    
    September 2019
38. TAKAHATA K, Kimura Y, Sahara N, Koga S, et al
    PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury.
    Brain. 2019 Sep 2. pii: 5556830. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2019
39. WILSON H, Dervenoulas G, Pagano G, Tyacke RJ, et al
    Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study.
    Brain. 2019 Aug 26. pii: 5554562. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2019
40. GAUBERT S, Raimondo F, Houot M, Corsi MC, et al
    EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Brain. 2019 Jun 18. pii: 5519996. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. MAASS A, Berron D, Harrison TM, Adams JN, et al
    Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Brain. 2019 Jun 14. pii: 5519092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. AVRAM M, Brandl F, Cabello J, Leucht C, et al
    Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms.
    Brain. 2019;142:1813-1826.
    PubMed     Abstract available
    
    
    April 2019
43. KNOPMAN DS, Lundt ES, Therneau TM, Vemuri P, et al
    Entorhinal cortex tau, amyloid-beta, cortical thickness and memory performance in non-demented subjects.
    Brain. 2019;142:1148-1160.
    PubMed     Abstract available
    
    
    February 2019
44. FRANZMEIER N, Rubinski A, Neitzel J, Kim Y, et al
    Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.
    Brain. 2019 Feb 15. pii: 5321130. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. GORDON BA, Blazey TM, Christensen J, Dincer A, et al
    Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Brain. 2019 Feb 11. pii: 5315649. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2019
46. PARK JC, Han SH, Yi D, Byun MS, et al
    Plasma tau/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Brain. 2019 Jan 21. pii: 5292577. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2018
47. KAUNZNER UW, Kang Y, Zhang S, Morris E, et al
    Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
    Brain. 2018 Dec 15. pii: 5250435. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2018
48. DANI M, Wood M, Mizoguchi R, Fan Z, et al
    Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Brain. 2018 Jul 20. pii: 5056962. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. GROTHE MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, et al
    Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Brain. 2018 Jul 16. pii: 5054650. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2018
50. MORRIS RS, Simon Jones P, Alawneh JA, Hong YT, et al
    Relationships between selective neuronal loss and microglial activation after ischaemic stroke in man.
    Brain. 2018 May 9. pii: 4994388. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. SMITH CB, Schmidt KC
    Measurement of regional rates of protein synthesis in human brain in vivo with L-[1-11C]-leucine PET.
    Brain. 2018 May 3. pii: 4992170. doi: 10.1093.
    PubMed    
    
    
    
52. SMEETS JSJ, van Loon LJC
    Reply: Measurement of regional rates of protein synthesis in human brain in vivo with L-[1-11C]-leucine PET.
    Brain. 2018 May 3. pii: 4992171. doi: 10.1093.
    PubMed    
    
    
    
53. HANSSON O, Mormino EC
    Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
    Brain. 2018;141:1241-1244.
    PubMed    
    
    
    April 2018
54. SABRI O, Meyer PM, Graf S, Hesse S, et al
    Cognitive correlates of alpha4beta2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Brain. 2018 Apr 17. pii: 4974320. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. MISHRA S, Blazey TM, Holtzman DM, Cruchaga C, et al
    Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE varepsilon4 genotype.
    Brain. 2018 Apr 17. pii: 4974818. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2018
56. HAMELIN L, Lagarde J, Dorothee G, Potier MC, et al
    Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
    Brain. 2018 Mar 28. pii: 4955843. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. BOTHA H, Mantyh WG, Murray ME, Knopman DS, et al
    FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
    Brain. 2018 Mar 12. pii: 4929906. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. JACK CR JR, Wiste HJ, Schwarz CG, Lowe VJ, et al
    Longitudinal tau PET in ageing and Alzheimer's disease.
    Brain. 2018 Mar 12. pii: 4929907. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. CHHATWAL JP, Schultz AP, Johnson KA, Hedden T, et al
    Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.
    Brain. 2018 Mar 7. pii: 4924520. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. NAKAMURA A, Cuesta P, Fernandez A, Arahata Y, et al
    Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Brain. 2018 Mar 7. pii: 4924218. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2018
61. HOENIG MC, Bischof GN, Seemiller J, Hammes J, et al
    Networks of tau distribution in Alzheimer's disease.
    Brain. 2018 Jan 5. pii: 4791255. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. RICHTER N, Beckers N, Onur OA, Dietlein M, et al
    Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Brain. 2018 Jan 4. pii: 4788772. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
    Brain. 2018 Jan 4. pii: 4788771. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2017
64. COPE TE, Rittman T, Borchert RJ, Jones PS, et al
    Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Dec 26. pii: 4775021. doi: 10.1093.
    PubMed    
    
    
    
65. SOMMERAUER M, Fedorova TD, Hansen AK, Knudsen K, et al
    Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
    Brain. 2017 Dec 18. pii: 4759463. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. LOWE VJ, Wiste HJ, Senjem ML, Weigand SD, et al
    Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Brain. 2017 Dec 8. pii: 4712020. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. MUTLU J, Landeau B, Gaubert M, de La Sayette V, et al
    Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Brain. 2017;140:3317-3328.
    PubMed    
    
    
    November 2017
68. GAXIOLA-VALDEZ I, Singh S, Perera T, Sandy S, et al
    Seizure onset zone localization using postictal hypoperfusion detected by arterial spin labelling MRI.
    Brain. 2017;140:2895-2911.
    PubMed     Abstract available
    
    
    October 2017
69. BEJANIN A, Schonhaut DR, La Joie R, Kramer JH, et al
    Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Brain. 2017 Oct 7. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2017
70. DATTA G, Colasanti A, Rabiner EA, Gunn RN, et al
    Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Brain. 2017 Sep 23. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. SCHOLL M, Ossenkoppele R, Strandberg O, Palmqvist S, et al
    Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Brain. 2017;140:2286-2294.
    PubMed     Abstract available
    
    
    August 2017
72. AYTON S, Fazlollahi A, Bourgeat P, Raniga P, et al
    Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline.
    Brain. 2017;140:2112-2119.
    PubMed     Abstract available
    
    
    
73. HONG SJ, Bernhardt BC, Gill RS, Bernasconi N, et al
    The spectrum of structural and functional network alterations in malformations of cortical development.
    Brain. 2017;140:2133-2143.
    PubMed     Abstract available
    
    
    
74. CHENNU S, Annen J, Wannez S, Thibaut A, et al
    Brain networks predict metabolism, diagnosis and prognosis at the bedside in disorders of consciousness.
    Brain. 2017;140:2120-2132.
    PubMed     Abstract available
    
    
    July 2017
75. TOUSSEYN S, Krishnan B, Wang ZI, Wongwiangjunt S, et al
    Connectivity in ictal single photon emission computed tomography perfusion: a cortico-cortical evoked potential study.
    Brain. 2017;140:1872-1884.
    PubMed     Abstract available
    
    
    
76. YEW B, Nation DA
    Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Brain. 2017;140:1987-2001.
    PubMed     Abstract available
    
    
    
77. CHARIDIMOU A, Boulouis G, Gurol ME, Ayata C, et al
    Emerging concepts in sporadic cerebral amyloid angiopathy.
    Brain. 2017;140:1829-1850.
    PubMed     Abstract available
    
    
    May 2017
78. PARBO P, Ismail R, Hansen KV, Amidi A, et al
    Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. BUTCHER NJ, Marras C, Pondal M, Rusjan P, et al
    Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease.
    Brain. 2017;140:1371-1383.
    PubMed     Abstract available
    
    
    
80. TOSUN D, Landau S, Aisen PS, Petersen RC, et al
    Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals.
    Brain. 2017;140:1499-1512.
    PubMed     Abstract available
    
    
    March 2017
81. ROBERTS BR, Lind M, Wagen AZ, Rembach A, et al
    Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET.
    Brain. 2017 Mar 5. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2017
82. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2017
84. FAN Z, Brooks DJ, Okello A, Edison P, et al
    An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain. 2017 Jan 24. pii: aww349. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. SCHOBERL F, Feil K, Xiong G, Bartenstein P, et al
    Pathological ponto-cerebello-thalamo-cortical activations in primary orthostatic tremor during lying and stance.
    Brain. 2017;140.
    PubMed     Abstract available
    
    
    December 2016
86. KAWANO H, Bivard A, Lin L, Ma H, et al
    Perfusion computed tomography in patients with stroke thrombolysis.
    Brain. 2016 Dec 31. pii: aww338. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2016
87. O'SULLIVAN MJ, Vann SD
    Amyloid imaging and Alzheimer's disease: the unsolved cases.
    Brain. 2016;139.
    PubMed    
    
    
    June 2016
88. CHETELAT G, Ossenkoppele R, Villemagne VL, Perrotin A, et al
    Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Brain. 2016.
    PubMed     Abstract available
    
    
    May 2016
89. OH H, Madison C, Baker S, Rabinovici G, et al
    Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Brain. 2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: